Original paper
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
Abstract
Corona Virus Disease (CoVID-19) is an emerging public health problem rapidly spread globally. New treatment options for patients with severe symptoms and ways of reducing transmission in the community are taken into consideration. A retrospective study was conducted in the Department of Infectious Diseases of Alexandroupolis (Greece) including 16 patients with CoVID-19. They were classified into two groups, A and B. Group A received...
Paper Details
Title
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
Published Date
Jun 12, 2020
Journal
Volume
33
Issue
3
Pages
193 - 197
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History